RT Journal Article
SR Electronic
T1 System-wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep proteome and phosphoproteome analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253675
DO 10.1101/2021.03.19.21253675
A1 Kaneko, Tomonori
A1 Esmail, Sally
A1 Voss, Courtney
A1 Martin, Claudio M.
A1 Slessarev, Marat
A1 Hovey, Owen
A1 Liu, Xuguang
A1 Ye, Mingliang
A1 Kim, Sung
A1 Fraser, Douglas
A1 Li, Shawn SC
YR 2021
UL http://medrxiv.org/content/early/2021/03/25/2021.03.19.21253675.abstract
AB The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has become a global crisis. To gain systems-level insights into its pathogenesis, we compared the blood proteome and phosphoproteome of ICU patients with or without SARS-CoV-2 infection, and healthy control subjects by quantitative mass spectrometry. We find that COVID-19 is marked with hyperactive T cell and B cell signaling, compromised innate immune response, and dysregulated inflammation, coagulation, metabolism, RNA splicing, transcription and translation pathways. SARS-CoV-2 infection causes global reprogramming of the kinome and kinase-substrate network, resulting in defective antiviral defense via the CK2-OPN-IL-12/IFN-α/β axis, lymphocyte cell death via aberrant JAK/STAT signaling, and inactivation of innate immune cells via inhibitory SIRPA, SIGLEC and SLAM family receptor signaling. Our work identifies CK2, SYK, JAK3, TYK2 and IL-12 as potential targets for immunomodulatory treatment of severe COVID-19 and provides a valuable approach and resource for deciphering the mechanism of pathogen-host interactions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Toronto Open Access COVID-19 Protein Manufacturing Center received funding from the Toronto COVID-19 Action Fund. We acknowledge funding from the Ontario Research Fund-COVID-19 Rapid Research Fund, Western University (Research), the Departments of Medicine and Pediatrics at Western University, the Lawson Health Research Institute (https://www.lawsonresearch.ca/), the London Health Sciences Foundation (https://lhsf.ca/), and the AMOSO Innovation Fund. SE was supported by a Post-Doctoral Fellowship from the National Science and Engineering Council of Canada. SSCL holds a Canada Research Chair in Molecular and Epigenetic Basis of Cancer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Western University, Human Research Ethics Board (study number: 116284).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometry data are available from the PRIDE databse accession PXD024087.